Q2 2019 13F Holders as of 30 Jun 2019
-
Type / Class
-
Equity / COM
-
Total 13F shares
-
26,753,528
-
Share change
-
+4,544,159
-
Total reported value
-
$2,128,534,998
-
Put/Call ratio
-
78%
-
Price per share
-
$79.57
-
Number of holders
-
193
-
Value change
-
+$319,846,105
-
Number of buys
-
126
-
Number of sells
-
71
Institutional Holders of INTERCEPT PHARMACEUTICALS IN - COM (ICPT) as of Q2 2019
As of 30 Jun 2019,
INTERCEPT PHARMACEUTICALS IN - COM (ICPT) was held by
193 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
26,753,528 shares.
The largest 10 holders included
FMR LLC, VANGUARD GROUP INC, BlackRock Inc., JPMORGAN CHASE & CO, STATE STREET CORP, FIRST TRUST ADVISORS LP, CITADEL ADVISORS LLC, Senvest Management, LLC, Sarissa Capital Management LP, and Bellevue Group AG.
This page lists
193
institutional shareholders reporting positions in this security
for the Q2 2019 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.